Abstract
Among the secondary outcomes, omalizumab treatment was associated with lower symptom severity scores (Mean SS Median Score and Average SS Median Score) in three trials, lower Mean Rescue Medication Score in two trials, lower number of doses of rescue medications in one trial, and comparable adverse drug reactions in two trials.